Invesco Portfolio holdings
Invesco Ltd., founded in 1978 and headquartered in Atlanta, Georgia, is a global investment management firm managing hundreds of billions in assets across a diverse range of products, including mutual funds, exchange-traded funds (ETFs), and institutional portfolios. Known for its blend of active and passive investment strategies, Invesco serves individual investors, financial advisors, and institutions, with a strong presence in North America, Europe, and Asia, bolstered by acquisitions like OppenheimerFunds in 2019. The firm offers specialized solutions in equities, fixed income, real estate, and alternatives, leveraging its global research capabilities to cater to varying market needs. Invesco’s commitment to innovation and client-focused investing has solidified its reputation as a versatile player in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.45B |
| 2 |
Apple
AAPL
|
+$814M |
| 3 |
NVIDIA
NVDA
|
+$700M |
| 4 |
Broadcom
AVGO
|
+$647M |
| 5 |
Shopify
SHOP
|
+$593M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$701M |
| 2 |
Johnson & Johnson
JNJ
|
+$685M |
| 3 |
Discover Financial Services
DFS
|
+$484M |
| 4 |
Meta Platforms (Facebook)
META
|
+$407M |
| 5 |
HubSpot
HUBS
|
+$394M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.47% |
| 2 | Financials | 12.85% |
| 3 | Industrials | 11.86% |
| 4 | Consumer Discretionary | 10.16% |
| 5 | Healthcare | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3601
Precigen
PGEN
$2.36B
| $89.4K | ﹤0.01% |
62,955
+19,149
| +44% | +$27.2K |
2014 Q4
42 quarters
|
|
3602
Vox Royalty Corp
VOXR
$350M
| $88.7K | ﹤0.01% |
+28,071
| New | +$92.5K |
2025 Q2
0 quarters
|
|
3603
Treace Medical Concepts
TMCI
$258M
| $88.5K | ﹤0.01% |
15,051
+2,362
| +19% | +$15.4K |
2021 Q4
14 quarters
|
|
3604
Pliant Therapeutics
PLRX
$57M
| $85.3K | ﹤0.01% |
73,494
+4,531
| +7% | +$6.4K |
2023 Q2
8 quarters
|
|
3605
Yiren Digital
YRD
$68.6M
| $83.9K | ﹤0.01% |
14,291
-822
| -5% | -$5.17K |
2024 Q4
2 quarters
|
|
3606
Westrock Coffee
WEST
$820M
| $82.4K | ﹤0.01% |
14,387
+129
| +0.9% | +$833 |
2023 Q2
8 quarters
|
|
3607
Purple Innovation
PRPL
$10.1M
| $82.3K | ﹤0.01% |
4,516
-3,292
| -42% | -$60.6K |
2020 Q1
21 quarters
|
|
3608
Lifetime Brands
LCUT
$192M
| $82K | ﹤0.01% |
16,082
-14,887
| -48% | -$55.4K |
2024 Q1
5 quarters
|
|
3609
DELISTED
Astria Therapeutics
ATXS
| $81.3K | ﹤0.01% |
15,162
-2,389
| -14% | -$11.6K |
2023 Q2
8 quarters
|
|
3610
HUHUTECH International Group
HUHU
$62.9M
| $80.8K | ﹤0.01% |
+16,630
| New | +$78.7K |
2025 Q2
0 quarters
|
|
3611
Eledon Pharmaceuticals
ELDN
$177M
| $80.6K | ﹤0.01% |
+29,740
| New | +$89.2K |
2025 Q2
0 quarters
|
|
3612
KORU Medical Systems
KRMD
$139M
| $79.9K | ﹤0.01% |
+22,325
| New | +$63.4K |
2025 Q2
0 quarters
|
|
3613
Starling Oncology
STLN
$688M
| $79.4K | ﹤0.01% |
+38,708
| New | +$96.8K |
2025 Q2
0 quarters
|
|
3614
Riverview Bancorp
RVSB
$120M
| $78.6K | ﹤0.01% |
+14,298
| New | +$82.7K |
2025 Q2
0 quarters
|
|
|
OPI
3615
DELISTED
Office Properties Income Trust
OPI
| $77K | ﹤0.01% |
311,769
-178,193
| -36% | -$50.1K |
2019 Q1
25 quarters
|
|
3616
Aura Biosciences
AURA
$639M
| $76.5K | ﹤0.01% |
+12,218
| New | +$71.5K |
2025 Q2
0 quarters
|
|
3617
Perspective Therapeutics
CATX
$259M
| $76.4K | ﹤0.01% |
22,209
-533
| -2% | -$1.41K |
2024 Q2
4 quarters
|
|
|
FFAI
3618
Faraday Future Intelligent Electric
FFAI
$5.02M
| $75.7K | ﹤0.01% |
+300
| New | +$55.1K |
2025 Q2
0 quarters
|
|
3619
Cardiff Oncology
CRDF
$72.5M
| $75K | ﹤0.01% |
23,795
+4,749
| +25% | +$14.5K |
2024 Q2
4 quarters
|
|
3620
Liberty Latin America Class A
LILA
$1.58B
| $74.8K | ﹤0.01% |
18,060
+340
| +2% | +$1.23K |
2019 Q1
25 quarters
|
|
|
ZSPC
3621
DELISTED
ZSPACE INC NEW
ZSPC
| $74.8K | ﹤0.01% |
917
| – | – |
2025 Q1
1 quarter
|
|
3622
Zevia
ZVIA
$88M
| $74.4K | ﹤0.01% |
+23,094
| New | +$60.8K |
2025 Q2
0 quarters
|
|
3623
MacroGenics
MGNX
$208M
| $73.8K | ﹤0.01% |
61,032
-7,345
| -11% | -$10.7K |
2014 Q4
42 quarters
|
|
3624
Sutro Biopharma
STRO
$182M
| $73.8K | ﹤0.01% |
10,332
+1,118
| +12% | +$9.14K |
2020 Q4
18 quarters
|
|
3625
Protara Therapeutics
TARA
$143M
| $72.5K | ﹤0.01% |
+23,935
| New | +$82.6K |
2025 Q2
0 quarters
|
|
Similar funds
Invesco's Q2 2025 Portfolio in Review
As of Q2 2025, Invesco held 3,922 positions worth $588B, up 11% from $528B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Invesco's Q2 2025 filing shows 165 new, 1,670 increased, 1,835 reduced and 165 closed positions. Its largest new stake was QXO Inc: 27,561,664 shares worth $594M. The largest sale was UnitedHealth, an estimated $701M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 23% a quarter earlier, followed by Financials and Industrials.
- Invesco's largest Q2 2025 buy was QXO Inc: 27,561,664 shares worth $594M.
- Invesco added most to Microsoft in Q2 2025, an estimated $1.45B increase.
- Invesco's biggest Q2 2025 reduction was UnitedHealth, cutting an estimated $701M.
- Invesco fully exited Discover Financial Services in Q2 2025, selling an estimated $484M.
- Invesco's ten largest holdings make up 20% of its $588B portfolio in Q2 2025.
- Invesco opened 165 new positions and closed 165 in Q2 2025.
- Invesco's portfolio value rose 11% quarter-over-quarter to $588B.
Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.